# A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

> **NCT07673029** · PHASE3 · RECRUITING · sponsor: **GeneQuantum Healthcare (Suzhou) Co., Ltd.** · enrollment: 228 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** GQ1005
- **DRUG:** T-DM1

## Key facts

- **NCT ID:** NCT07673029
- **Lead sponsor:** GeneQuantum Healthcare (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2027-01-09
- **Final completion:** 2028-01-09
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673029, "A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07673029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*